Quantum-Si incorporated
NASDAQ:QSIBiotechnology
+$0.05 today
- Market cap
- $213.79M
- Beta
- 3.17
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.48
Volume 10.47M
Average 5.64M
QSI Sales of Investments
Cash received from selling or redeeming investments.
Quantum-Si incorporatedNASDAQ: QSI
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments growth accelerates
Q1 FY2026 sales of investments of $104.7M rose 20.6% year over year, ahead of the -2.2% change in trailing-twelve-month sales of investments. Sequentially, it fell 10.0% from the prior quarter. Over 3 fiscal years it compounded at +36.6% a year.
Context
- Sales of investments amounted to 15549.2% of revenue in FY2025, up 4385.0 pp from a year earlier.
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.6% holds above the trailing-twelve-month pace of -2.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 378.78M USD
- Year-over-year change
- +10.9%
- 4-year CAGR
- -4.0%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 378.78M | +10.9% |
| FY2024 | 2024-12-31 | 341.4M | +25.3% |
| FY2023 | 2023-12-31 | 272.51M | +83.2% |
| FY2022 | 2022-12-31 | 148.76M | -66.6% |
| FY2021 | 2021-12-31 | 445.17M | — |
Sales of Investments vs competitors
How QSI compares with its peers on the latest reported figures
- QSI's LTM Mar 2026 sales of investments of $396.68M is the 2nd largest of the 11 companies compared; the peer median is $183.5M.
- Its year-over-year change of -2.2% is the 7th highest of 9, against a peer median of +29.6%.
- Sales of investments amounts to 21418.9% of revenue for QSI, versus a peer median of 563.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $521.77M | +2508.8% | — | 563.5% | |
| LTM Mar 2026 | $396.68M | -2.2% | +36.6% | 21418.9% | |
| LTM Mar 2026 | $364.75M | +0.0% | +11.7% | — | |
| LTM Mar 2026 | $275.9M | -45.0% | +31.2% | — | |
| LTM Mar 2026 | $268.88M | +47.8% | -5.7% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $212.43M | +408.8% | — | — |
| LTM Mar 2026 | $154.57M | +38.8% | — | 429355.6% | |
| LTM Mar 2026 | $145M | +20.3% | +31.3% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $0 | — | +243.9% | — |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding QSI) | $183.5M | +29.6% | +31.2% | 563.5% | |
Competitors are the stored peer set for QSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (94.99M) | (132.44M) | (95.96M) | (101.01M) | (101.34M) |
| Depreciation & Amortization | 1.04M | 2.58M | 4.16M | 4.6M | 4.45M |
| Deferred Income Tax | 714K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.92M | 11.21M | 8.52M | 8.89M | 10.77M |
| Change in Working Capital | 1.47M | 3.05M | (3.2M) | 4.64M | (4.58M) |
| Accounts Receivables | 0 | 0 | (368K) | (1.09M) | 626K |
| Inventory | 0 | 0 | 286K | 4.34M | (2.01M) |
| Accounts Payables | 709K | 721K | (1.22M) | 390K | (338K) |
| Other Working Capital | 758K | 2.33M | (1.89M) | 1M | (2.86M) |
| Other Non-Cash Items | 36K | 25.04M | (7.55M) | (4.92M) | (4.03M) |
| Operating Cash Flow | (66.81M) | (90.56M) | (94.04M) | (87.8M) | (94.72M) |
| Capital Expenditures | (5.76M) | (10.74M) | (5.27M) | (4.58M) | (2.52M) |
| Acquisitions (Net) | (4.63M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (440.54M) | (834K) | (123.81M) | (369.43M) | (404.58M) |
| Sales of Investments | 445.17M | 148.76M | 272.51M | 341.4M | 378.78M |
| Other Investing Activities | (445.17M) | 0 | (763K) | (59K) | 0 |
| Investing Cash Flow | (450.94M) | 137.19M | 143.43M | (32.68M) | (28.32M) |
| Debt Repayment | (1.78M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 512.79M | 2.76M | 0 | 34.79M | 95.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.61M | (848K) | 149K | 1.09M | 1K |
| Financing Cash Flow | 516.63M | 1.91M | 149K | 35.88M | 95.42M |
| Effect of Forex Changes | 0 | 0 | 0 | (25K) | 12K |
| Net Change in Cash | (1.13M) | 48.53M | 49.54M | (84.62M) | (27.6M) |
| Free Cash Flow | (72.58M) | (101.3M) | (99.31M) | (92.38M) | (97.23M) |
Quantum-Si incorporated
NASDAQ:QSI
Intrinsic Alpha fair value
Locked
Current Price
$1.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.